NCT03059693View on ClinicalTrials.gov

Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 13, 2016

Study Completion Date

July 24, 2016

Conditions
Dermatitis, Atopic
Interventions
DRUG

HAT1 topical cream

DRUG

Vehicle cream

Sponsors

Lead Sponsor

Haus Bioceuticals
All Listed Sponsors
lead

Haus Bioceuticals

INDUSTRY